Sevabertinib

Definition

An orally bioavailable, mutant-selective, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), with potential antineoplastic activity. Upon oral administration, sevabertinib targets, binds to, and inhibits the activity of EGFR and HER2 with exon20 insertion mutations, as well as EGFR with C797X mutations, thereby preventing EGFR- and HER2-mediated signaling. This may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization.

Also known as BAY 2927088, BAY-2927088, BAY2927088, EGFR/HER2 Mutant-selective Inhibitor BAY2927088, Hyrnuo, SEVABERTINIB — per NCIT

Also identified as

• ATC L01EH06 per RXNORM
• NCIT NCIT:C185187 per NCIT
• UNII 2A7VPM5RWH per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.